全身麻酔薬の市場規模、シェア、動向分析レポート：薬物別、投与経路別、最終用途別、用途別、地域別、セグメント予測、2025年～2030年

全身麻酔薬市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の全身麻酔薬市場規模は2030年までに65億6,000万米ドルに達し、2025～2030年にかけて3.68%のCAGRで成長すると予測されています。

この予測成長は、手術量の増加、麻酔技術の進歩、慢性疾患の有病率の上昇、政府の支援策など、いくつかの重要な要因によってもたらされます。世界保健機関（WHO）は、医療へのアクセス向上と選択的手術と緊急手術の増加により、手術件数が増加していると推定しています。2022年だけでも、世界全体で約2,000万人の新規がん患者と970万人のがん関連死が発生しており、外科的介入が急増していることが浮き彫りになっています。このような外科手術の増加は、手術中の患者の安全性と快適性を確保するために不可欠である全身麻酔の需要増に拍車をかけています。

医療へのアクセスを拡大し、インフラを改善するための政府の取り組みは、市場の成長をさらに後押ししています。北米や欧州を含む多くの地域では、医療改革と資金援助により、外科手術サービスの利用可能性が高まり、医療の質が向上しています。例えば、米国では「医療費負担適正化法（Affordable Care Act）」が施行され、他の国々でも同様の取り組みが行われているため、手術へのアクセスが拡大し、全身麻酔薬の需要増につながっています。医療インフラや新しい医療施設への投資は、麻酔市場を強化します。

麻酔の技術的進歩は、市場成長に重要な役割を果たしています。標的制御点滴システム、安全性プロファイルを改善した新しい麻酔薬、モニタリング技術の強化などの技術革新は、麻酔の効率性と有効性に貢献しています。例えば、より速い麻酔開始時間と回復時間を持つ麻酔薬の開発は、患者の転帰を改善し、需要を牽引します。

全身麻酔薬市場のレポートハイライト

• 2024年には、プロポフォール部門が25.52%の大幅なシェアで市場を席巻し、予測期間中に最も速いCAGRで成長する見込みです。プロポフォールは、患者の快適性と手技の効率性を高める迅速な発現と迅速な回復時間で有名です。
• 静脈内セグメントは2024年に最大の収益シェアを占め、予測期間中のCAGRも3.9％と最も速い成長が見込まれています。
• 2024年には、人工膝関節置換術と人工股関節置換術のセグメントが市場を独占し、かなりの収益シェアを獲得しました。この優位性は、変形性関節症の有病率の増加、手術技術の進歩、人口動向によってもたらされます。
• 2024年には、病院部門が市場を独占し、67.05％の大幅な収益シェアを獲得しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 全身麻酔薬市場の変数、動向、範囲

• 市場系統の展望
  • 親市場の展望
  • 関連/付随市場の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 全身麻酔薬市場分析ツール
  • 産業分析-ポーターのファイブフォース分析
  • PESTEL分析

第4章 全身麻酔薬市場： 薬剤別、推定・動向分析

• 世界の全身麻酔薬市場：薬剤ダッシュボード
• 世界の全身麻酔薬市場：薬剤変動分析
• 世界の全身麻酔薬市場：薬剤変動分析
• セボフルラン
• プロポフォール
• デクスメデトミジン
• レミフェンタニル
• デスフルラン
• ミダゾラム
• その他

第5章 全身麻酔薬市場：投与経路別、推定・動向分析

• 世界の全身麻酔薬市場：投与経路ダッシュボード
• 世界の全身麻酔薬市場：投与経路変動分析
• 投与経路別収益
• 静脈内
• 吸入

第6章 全身麻酔薬市場：最終用途別、推定・動向分析

• 世界の全身麻酔薬市場：最終用途ダッシュボード
• 世界の全身麻酔薬市場：最終用途変動分析
• 最終用途別、収益
• 病院
• 外来手術センター
• その他

第7章 全身麻酔薬市場：用途別、推定・動向分析

• 世界の全身麻酔薬市場：用途ダッシュボード
• 世界の全身麻酔薬市場：用途変動分析
• 用途別収益
• 心臓手術
• がん
• 一般外科
• 人工膝関節置換術と人工股関節置換術
• その他

第8章 全身麻酔薬市場：薬剤、投与経路、最終用途、用途による地域別、推定・動向分析

• 地域ダッシュボード
• 市場規模、予測動向分析、2018～2030年
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 企業/競合の分類
• ベンダー情勢
  • 主要販売代理店とチャネルパートナー一覧
  • 主要企業の市場シェア分析、2024年
  • Baxter International Inc.
  • AstraZeneca
  • AbbVie Inc.
  • B. Braun Melsungen AG
  • Fresenius SE &Co. KgaA
  • Pfizer
  • Hospira Inc.
  • Aspen Pharmacare Holdings Limited
  • Hikama Pharmaceuticals plc
  • Abbott Laboratories

List of Tables

• Table 1 List Of Abbreviation
• Table 2 North America General Anesthesia Drugs Market, By Region, 2018 - 2030 (USD Million)
• Table 3 North America General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 4 North America General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 5 North America General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
• Table 6 North America General Anesthesia Drugs Market, Application, 2018 - 2030 (USD Million)
• Table 7 U.S. General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 8 U.S. General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 9 U.S. General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
• Table 10 U.S. General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 11 Canada General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 12 Canada General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 13 Canada General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
• Table 14 Canada General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 15 Mexico General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 16 Mexico General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 17 Mexico General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
• Table 18 Mexico General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 19 Europe General Anesthesia Drugs Market, By Region, 2018 - 2030 (USD Million)
• Table 20 Europe General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 21 Europe General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 22 Europe General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
• Table 23 Europe General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 24 Germany General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 25 Germany General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 26 Germany General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
• Table 27 Germany General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 28 UK General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 29 UK General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 30 UK General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
• Table 31 UK General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 32 France General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 33 France General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 34 France General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
• Table 35 France General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 36 Italy General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 37 Italy General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 38 Italy General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
• Table 39 Italy General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 40 Spain General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 41 Spain General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 42 Spain General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
• Table 43 Spain General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 44 Denmark General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 45 Denmark General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 46 Denmark General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
• Table 47 Denmark General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 48 Sweden General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 49 Sweden General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 50 Sweden General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
• Table 51 Sweden General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 52 Norway General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 53 Norway General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 54 Norway General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
• Table 55 Norway General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 56 Asia Pacific General Anesthesia Drugs Market, By Region, 2018 - 2030 (USD Million)
• Table 57 Asia Pacific General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 58 Asia Pacific General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 59 Asia Pacific General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
• Table 60 Asia Pacific General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 61 China General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 62 China General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 63 China General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
• Table 64 China General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 65 Japan General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 66 Japan General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 67 Japan General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
• Table 68 Japan General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 69 India General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 70 India General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 71 India General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
• Table 72 India General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 73 South Korea General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 74 South Korea General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 75 South Korea General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
• Table 76 South Korea General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 77 Australia General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 78 Australia General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 79 Australia General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
• Table 80 Australia General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 81 Thailand General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 82 Thailand General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 83 Thailand General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
• Table 84 Thailand General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 85 Latin America General Anesthesia Drugs Market, By Region, 2018 - 2030 (USD Million)
• Table 86 Latin America General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 87 Latin America General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 88 Latin America General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
• Table 89 Latin America General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 90 Brazil General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 91 Brazil General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 92 Brazil General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
• Table 93 Brazil General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 94 Argentina General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 95 Argentina General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 96 Argentina General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
• Table 97 Argentina General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 98 MEA General Anesthesia Drugs Market, By Region, 2018 - 2030 (USD Million)
• Table 99 MEA General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 100 MEA General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 101 MEA General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
• Table 102 MEA General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 103 South Africa General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 104 South Africa General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 105 South Africa General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
• Table 106 South Africa General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 107 Saudi Arabia General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 108 Saudi Arabia General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 109 Saudi Arabia General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
• Table 110 Saudi Arabia General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 111 UAE General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 112 UAE General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 113 UAE General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
• Table 114 UAE General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 115 Kuwait General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 116 Kuwait General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 117 Kuwait General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
• Table 118 Kuwait General Anesthesia Drugs Market, By Application, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Primary interviews in Europe
• Fig. 6 Primary interviews in APAC
• Fig. 7 Primary interviews in Latin America
• Fig. 8 Primary interviews in MEA
• Fig. 9 Market research approaches
• Fig. 10 Value-chain-based sizing & forecasting
• Fig. 11 QFD modeling for market share assessment
• Fig. 12 Market formulation & validation
• Fig. 13 General Anesthesia Drugs Market: Market Outlook
• Fig. 14 Colorectal Surgery Competitive Insights
• Fig. 15 Parent market outlook
• Fig. 16 Related/ancillary market outlook
• Fig. 17 General Anesthesia Drugs Market Driver Impact
• Fig. 18 General Anesthesia Drugs Market Restraint Impact
• Fig. 19 General Anesthesia Drugs Market Strategic Initiatives Analysis
• Fig. 20 General Anesthesia Drugs Market: Drug Movement Analysis
• Fig. 21 General Anesthesia Drugs Market: Drug Outlook and Key Takeaways
• Fig. 22 Sevoflurane market estimates and forecast, 2018 - 2030
• Fig. 23 Propofol market estimates and forecast, 2018 - 2030
• Fig. 24 Dexmedetomidine market estimates and forecast, 2018 - 2030
• Fig. 25 Remifentanil market estimates and forecast, 2018 - 2030
• Fig. 26 Desflurane market estimates and forecast, 2018 - 2030
• Fig. 27 Midazolam market estimates and forecast, 2018 - 2030
• Fig. 28 Others market estimates and forecast, 2018 - 2030
• Fig. 29 General Anesthesia Drugs Market: Route of Administration Movement Analysis
• Fig. 30 General Anesthesia Drugs Market: Route of Administration Outlook and Key Takeaways
• Fig. 31 Intravenous market estimates and forecast, 2018 - 2030
• Fig. 32 Inhaled market estimates and forecast, 2018 - 2030
• Fig. 33 General Anesthesia Drugs Market: End Use Movement Analysis
• Fig. 34 General Anesthesia Drugs Market: End Use Outlook and Key Takeaways
• Fig. 35 Hospitals market estimates and forecast, 2018 - 2030
• Fig. 36 Ambulatory Surgical Centers market estimates and forecast, 2018 - 2030
• Fig. 37 Others market estimates and forecast, 2018 - 2030
• Fig. 38 General Anesthesia Drugs Market: Application Movement Analysis
• Fig. 39 General Anesthesia Drugs Market: Application Outlook and Key Takeaways
• Fig. 40 Heart Surgeries market estimates and forecast, 2018 - 2030
• Fig. 41 Cancer market estimates and forecast, 2018 - 2030
• Fig. 42 General Surgery market estimates and forecast, 2018 - 2030
• Fig. 43 Knee and hip replacements market estimates and forecast, 2018 - 2030
• Fig. 44 Other market estimates and forecast, 2018 - 2030
• Fig. 45 Global General Anesthesia Drugs Market: Regional Movement Analysis
• Fig. 46 Global General Anesthesia Drugs Market: Regional Outlook and Key Takeaways
• Fig. 47 Global General Anesthesia Drugs Market share and leading players
• Fig. 48 North America, by country
• Fig. 49 North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 U.S. key country dynamics
• Fig. 51 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Canada key country dynamics
• Fig. 53 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Mexico key country dynamics
• Fig. 55 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 UK key country dynamics
• Fig. 58 UK market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Germany key country dynamics
• Fig. 60 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 France key country dynamics
• Fig. 62 France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Italy key country dynamics
• Fig. 64 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 65 Spain key country dynamics
• Fig. 66 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 67 Denmark key country dynamics
• Fig. 68 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 69 Sweden key country dynamics
• Fig. 70 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 71 Norway key country dynamics
• Fig. 72 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 73 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 74 China key country dynamics
• Fig. 75 China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 76 Japan key country dynamics
• Fig. 77 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 78 India key country dynamics
• Fig. 79 India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 80 Thailand key country dynamics
• Fig. 81 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 82 South Korea key country dynamics
• Fig. 83 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 84 Australia key country dynamics
• Fig. 85 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 86 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 87 Brazil key country dynamics
• Fig. 88 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 89 Argentina key country dynamics
• Fig. 90 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 91 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 92 South Africa key country dynamics
• Fig. 93 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 94 Saudi Arabia key country dynamics
• Fig. 95 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 96 UAE key country dynamics
• Fig. 97 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 98 Kuwait key country dynamics
• Fig. 99 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 100 Market share of key market players- General Anesthesia Drugs Market

General Anesthesia Drugs Market Growth & Trends:

The global general anesthesia drugs market size is projected to reach USD 6.56 billion by 2030, and projected to grow at a CAGR of 3.68% from 2025 to 2030, according to a new report by Grand View Research, Inc. This projected growth is driven by several critical factors, including increasing surgical volumes, advancements in anesthesia technology, rising prevalence of chronic diseases, and supportive government initiatives. The World Health Organization (WHO) estimates that the volume of surgeries is increasing due to greater access to healthcare and the growing number of elective and emergency procedures. In 2022 alone, there were nearly 20 million new cancer cases and 9.7 million cancer-related deaths globally, highlighting the surge in surgical interventions required. This increase in surgical activity is fueling a heightened demand for general anesthesia, as it is crucial for ensuring patient safety and comfort during operations.

Government initiatives to expand healthcare access and improve infrastructure further support market growth. In many regions, including North America and Europe, healthcare reforms and funding are increasing the availability of surgical services and improving the quality of care. For instance, the U.S. Affordable Care Act and similar initiatives in other countries are expanding surgery access, contributing to the higher demand for general anesthesia drugs. Investments in healthcare infrastructure and new healthcare facilities enhance the anesthesia market.

Technological advancements in anesthesia play a significant role in market growth. Innovations such as target-controlled infusion systems, new anesthetic agents with improved safety profiles, and enhanced monitoring technologies contribute to the efficiency and effectiveness of anesthesia. For instance, developing anesthetics with faster onset and recovery times improves patient outcomes and drives demand.

General Anesthesia Drugs Market Report Highlights:

• In 2024, the propofol segment dominated the market with a substantial share of 25.52% and is also expected to grow at the fastest CAGR during the forecast period. Propofol is renowned for its rapid onset and quick recovery times, which enhance patient comfort and procedural efficiency.
• The intravenous (IV) segment held the largest revenue share in 2024 and is also expected to grow at the fastest CAGR of 3.9% during the forecast period.
• In 2024, the knee and hip replacements segment dominated the market, capturing a substantial revenue share. This dominance is driven by the increasing prevalence of osteoarthritis, advancements in surgical techniques, and demographic trends.
• In 2024, the hospitals segment dominated the market, capturing a substantial revenue share of 67.05%.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug
  • 1.2.2. Route of Administration
  • 1.2.3. End Use
  • 1.2.4. Application
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug Outlook
  • 2.2.2. Route of Administration
  • 2.2.3. End Use
  • 2.2.4. Application
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. General Anesthesia Drugs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing Volume of Surgical Procedures
    • 3.2.1.2. Advancements In Anesthesia Technology
    • 3.2.1.3. Regulatory Developments
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Regulatory and Compliance Challenges
    • 3.2.2.2. Adverse Effects and Safety Concerns
• 3.3. General Anesthesia Drugs Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. General Anesthesia Drugs Market: Drug Estimates & Trend Analysis

• 4.1. Global General Anesthesia Drugs Market: Drug Dashboard
• 4.2. Global General Anesthesia Drugs Market: Drug Movement Analysis
• 4.3. Global General Anesthesia Drugs Market by Drug, Revenue
• 4.4. Sevoflurane
  • 4.4.1. Sevoflurane market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Propofol
  • 4.5.1. Propofol market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Dexmedetomidine
  • 4.6.1. Dexmedetomidine market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Remifentanil
  • 4.7.1. Remifentanil market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Desflurane
  • 4.8.1. Desflurane market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Midazolam
  • 4.9.1. Midazolam market estimates and forecasts 2018 to 2030 (USD Million)
• 4.10. Others
  • 4.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. General Anesthesia Drugs Market: Route of Administration Estimates & Trend Analysis

• 5.1. Global General Anesthesia Drugs Market: Route of Administration Dashboard
• 5.2. Global General Anesthesia Drugs Market: Route of Administration Movement Analysis
• 5.3. Global General Anesthesia Drugs Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
• 5.4. Intravenous
  • 5.4.1. Intravenous market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Inhaled
  • 5.5.1. Inhaled market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. General Anesthesia Drugs Market: End Use Estimates & Trend Analysis

• 6.1. Global General Anesthesia Drugs Market: End Use Dashboard
• 6.2. Global General Anesthesia Drugs Market: End Use Movement Analysis
• 6.3. Global General Anesthesia Drugs Market Estimates and Forecasts, By End Use, Revenue (USD Million)
• 6.4. Hospitals
  • 6.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Ambulatory Surgical Centers
  • 6.5.1. Ambulatory Surgical Centers market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. General Anesthesia Drugs Market: Application Estimates & Trend Analysis

• 7.1. Global General Anesthesia Drugs Market: Application Dashboard
• 7.2. Global General Anesthesia Drugs Market: Application Movement Analysis
• 7.3. Global General Anesthesia Drugs Market Estimates and Forecasts, By Application, Revenue (USD Million)
• 7.4. Heart Surgeries
  • 7.4.1. Heart Surgeries market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Cancer
  • 7.5.1. Cancer market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. General Surgery
  • 7.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Knee and hip replacements
  • 7.7.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Other
  • 7.8.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. General Anesthesia Drugs Market: Regional Estimates & Trend Analysis by Drug, Route of Administration, End Use and Application

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Vendor Landscape
  • 9.2.1. List of key distributors and channel partners
  • 9.2.2. Key company market share analysis, 2024
  • 9.2.3. Baxter International Inc.
    • 9.2.3.1. Company overview
    • 9.2.3.2. Financial performance
    • 9.2.3.3. Drug benchmarking
    • 9.2.3.4. Strategic initiatives
  • 9.2.4. AstraZeneca
    • 9.2.4.1. Company overview
    • 9.2.4.2. Financial performance
    • 9.2.4.3. Drug benchmarking
    • 9.2.4.4. Strategic initiatives
  • 9.2.5. AbbVie Inc.
    • 9.2.5.1. Company overview
    • 9.2.5.2. Financial performance
    • 9.2.5.3. Drug benchmarking
    • 9.2.5.4. Strategic initiatives
  • 9.2.6. B. Braun Melsungen AG
    • 9.2.6.1. Company overview
    • 9.2.6.2. Financial performance
    • 9.2.6.3. Drug benchmarking
    • 9.2.6.4. Strategic initiatives
  • 9.2.7. Fresenius SE & Co. KgaA
    • 9.2.7.1. Company overview
    • 9.2.7.2. Financial performance
    • 9.2.7.3. Drug benchmarking
    • 9.2.7.4. Strategic initiatives
  • 9.2.8. Pfizer
    • 9.2.8.1. Company overview
    • 9.2.8.2. Financial performance
    • 9.2.8.3. Drug benchmarking
    • 9.2.8.4. Strategic initiatives
  • 9.2.9. Hospira Inc.
    • 9.2.9.1. Company overview
    • 9.2.9.2. Financial performance
    • 9.2.9.3. Drug benchmarking
    • 9.2.9.4. Strategic initiatives
  • 9.2.10. Aspen Pharmacare Holdings Limited
    • 9.2.10.1. Company overview
    • 9.2.10.2. Financial performance
    • 9.2.10.3. Drug benchmarking
    • 9.2.10.4. Strategic initiatives
  • 9.2.11. Hikama Pharmaceuticals plc
    • 9.2.11.1. Company overview
    • 9.2.11.2. Financial performance
    • 9.2.11.3. Drug benchmarking
    • 9.2.11.4. Strategic initiatives
  • 9.2.12. Abbott Laboratories
    • 9.2.12.1. Company overview
    • 9.2.12.2. Financial performance
    • 9.2.12.3. Drug benchmarking
    • 9.2.12.4. Strategic initiatives